Research

Hodgkin Immunotherapy Effectiveness Study - Phase II/III

Immunomodulation After High Dose Myeloablative Therapy With Autologous Stem Cell Rescue for Refractory/Relapsed Hodgkin's Disease

Protocol Description

This Phase II/III Children's Oncology Group trial is studying the effectiveness of high-dose chemotherapy followed by autologous stem cell transplantation, cyclosporine, interferon gamma, and interleukin-2 as compared to high-dose chemotherapy followed by autologous stem cell transplantation only in treating patients with refractory or relapsed Hodgkin's lymphoma. Combining chemotherapy with autologous stem cell transplantation – transplanting the donor’s own stem cells – may allow physicians to give higher doses of chemotherapy drugs and kill more cancer cells.

Eligibility Criteria

Eligible candidates include children and young adults up through age 29 with Hodgkin disease that did not get better after initial treatment or that went away and then came back.
Males: Up through age 29
Females: Up through age 29

Requirements*
Participants will receive 2 courses of salvage induction therapy followed by protocol therapy within 2-5 weeks after. Phase II protocol includes immunotherapy and additional chemotherapy, and may also include radio therapy. In the Phase III portion of the study, participants are randomized into 2 groups – a repeat of Phase II protocol or Phase II protocol minus immunotherapy.
Visits: Number of visits will vary depending on the participant’s response to treatment.
Duration: This study is expected to take approximately one year and involves yearly follow-up examinations thereafter.

Status: Closed to Enrollment

Source of Support
Children’s Oncology Group (Study AHOD0121)
National Cancer Institute

Additional Resources
Children’s Oncology Group CureSearch
Study Description at National Institutes of Health